Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigate Risperidone for the Treatment of Schizophrenia in Adolescents

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00088075
First received: July 19, 2004
Last updated: June 6, 2011
Last verified: January 2011